BriaCell Therapeutics Corp. Common Shares (BCTX)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach BriaCell as a Graham-style skeptic. It is an immuno-oncology developer, and its lead asset Bria-IMT is in Phase 3 for end-stage breast cancer. That is scientific optionality, not a business with a moat. There is no revenue in the filed periods I was given, so there is no customer habit, pricing power, or durable competitive advantage to evaluate. Financial health is poor: FY2025 ended 2025-07-31 showed a net loss of $26.3 million; FY2024 showed a net loss of $4.8 million; FY2023 showed a net loss of $20.3 million. In fiscal Q3 2026, the quarter ended 2026-04-30, the net loss was $7.2 million. Trailing free cash flow was negative $30.0 million, a free cash flow yield of -92.9% against the $32.3 million market cap. FairStock calculations at the 2026-10-13 close show a P/E of -4.03, P/B of 1.12, ROE of -175.25%, ROCE of -90.84%, Piotroski 1/9, and Altman Z-score of -0.69. Those are not the marks of a fortress. The Lynch category is none because the company has lost money each of the last four years. Valuation is nearly impossible on earnings; the P/B calculation says roughly book value, but book is being consumed by cash burn. Growth cannot be measured from revenue, and the loss trajectory remains the key. This is a speculative clinical-stage equity with binary trial risk. At $3.71, the market is not paying for current profits; it is paying for possible future drug approval.

In plain English: BriaCell is a small cancer-drug developer whose lead treatment is in late-stage human testing for end-stage breast cancer. It has no reported sales and has kept losing money, so the business itself looks weak. At the 2026-10-13 close, the total value of its shares was about $32.3 million; without sales or profits, it is not possible to call the shares cheap or expensive on ordinary business numbers, and the price mostly reflects hope for the trials.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-04-30) · fiscal Q2 2026 10-Q (period ended 2026-01-31) · fiscal Q1 2026 10-Q (period ended 2025-10-31) · fiscal Q3 2025 10-Q (period ended 2025-04-30) · FY2025 10-K (period ended 2025-07-31) · FY2024 10-K (period ended 2024-07-31) · FY2023 10-K (period ended 2023-07-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer